Review: Optimal use of biologics in the management of Crohn’s disease
Remo Panaccione MD, FRCPC, Subrata Ghosh MD, FRCP, FRCP(E)
Therapeutic Advances in Gastroenterology · 2010
doi:10.1177/1756283x09357579 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Crohn’s disease (CD) is a chronic relapsing and remitting disorder of the gastrointestinal tract with no known cure. The inflammation that drives the disease can lead to debilitating symptoms and a number of complications that may lead to surgery. The introduction of biologic therapy a decade ago has offered a new option for patients failing conventional therapy. Over time, biologic therapy has also led to the desire to achieve treatment goals beyond the control of symptoms. In order to achieve short-term and long-term goals with these new agents, it is important to review how these therapies may be optimized for the best results.
Abstract licence: CC BY-NC
References44
40 more references, whose wording the paper’s licence keeps private.
All 44 referencesReads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.